Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


FDA Asks Endo Pharma to Pull Opana ER


 

In a highly unusual move, the U.S. Food and Drug Administration has requested Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. In a release on June 8, the agency said it is seeking removal based on concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.

"We are facing an opioid epidemic - a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," said FDA Commissioner Scott Gottlieb, MD. "We will continue to take regulatory steps when we see situations where an opioid product's risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse."

The FDA's decision is based on a review of all available postmarketing data, which demonstrated a significant shift in the route of abuse of Opana ER from nasal to injection following the product's reformulation. Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder (thrombotic microangiopathy). This decision follows a March 2017 FDA advisory committee meeting where a group of independent experts voted 18-8 that the benefits of reformulated Opana ER no longer outweigh its risks.

Opana ER was first approved in 2006 for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. In 2012, Endo replaced the original formulation of Opana ER with a new formulation intended to make the drug resistant to physical and chemical manipulation for abuse by snorting or injecting. While the product met the regulatory standards for approval, the FDA determined that the data did not show that the reformulation could be expected to meaningfully reduce abuse and declined the company's request to include labeling describing potentially abuse-deterrent properties for Opana ER. Now, with more information about the risks of the reformulated product, the agency is taking steps to remove the reformulated Opana ER from the market.

"The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak. When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market," said Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research. "This action will protect the public from further potential for misuse and abuse of this product."

The FDA has requested that the company voluntarily remove reformulated Opana ER from the market. Should the company choose not to remove the product, the agency intends to take steps to formally require its removal by withdrawing approval. In the interim, the FDA is making healthcare professionals and others aware of the particularly serious risks associated with the abuse of this product.

The FDA will continue to examine the risk-benefit profile of all approved opioid analgesic products and take further actions as appropriate as a part of our response to this public health crisis.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 
Share:

Related Articles:


Recent Articles

Physician Spotlight: Manny Sethi, MD: Leading by Example

Orthopaedic surgeon and community health advocate Manny Sethi, MD, is piloting a new model of healthcare for Tennesseans

Read More

Local Seniors Look to Exercise More, Eat Better in 2019

According to a new survey, Nashville seniors are ready to make the lifestyle changes necessary to improve health, increase mobility and reduce chronic pain.

Read More

Resolve to Address Obesity

Obesity and its comorbid conditions impact both lifespan and quality of life. However, not all obesity is created equal. Resolve to take simple steps help identify those most at risk for diabetes, cardiovascular disease and other complications and intervene.

Read More

Clover Health Flu Shot Monitor Finds Only 61% of Nashville Seniors Have Been Immunized This Season

With flu shot rates increasing only 20% over the past month, too many older Middle Tennessee residents remain unvaccinated going into the height of flu season

Read More

Jacobs Out at Acadia

Veteran healthcare CEO Joey Jacobs is out at Acadia Healthcare following a Sunday board meeting that ousted the behavioral health giant's well-known leader.

Read More

Moving beyond Wellness to Well-Being

Increasingly, healthcare providers are expanding their focus beyond physical wellness to take a more holistic view of well-being.

Read More

Seasonal Affective Disorder: The Recurring Winter Blues Storm

In the United States, 10 to 20 percent of people have a form of the winter blues, and about half a million people suffer from winter Seasonal Affective Disorder or SAD.

Read More

Competition Levels Drop in Health Insurance Markets across 25 States

Read More

Vanderbilt Comments on Patient Error, CMS Corrective Action Plan

Following a medication error last December that resulted in a patient death, Vanderbilt University Medical Center faced scrutiny by CMS, which could have potentially impacted Medicare reimbursement. However, on Nov. 29, the federal agency accepted a corrective action plan submitted by the city's academic medical center.

Read More

Lifepoint Health And Rcch Healthcare Partners Announce Completion Of Merger

Read More

Email Print
 
 

 

 


Tags:
Drug Abuse, Endo Pharmaceuticals, FDA, Food and Drug Administration, Opana ER, Opioid Addiction
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: